Zobrazeno 1 - 10
of 14
pro vyhledávání: '"H. Kocinsky"'
Autor:
N. Palakow, M. Pickering, B. Dixon, P. Walker, F. Fakhowri, I. Soomro, T. Cook, Z. Zhang, Z. Ahmad, H. Kocinsky
Publikováno v:
Kidney International Reports. 7:S458-S459
Autor:
M. Pickering, B. Dixon, P. Walker, F. Fakhowri, I. Soomro, T. Cook, Z. Zhang, Z. Ahmad, H. Kocinsky
Publikováno v:
Kidney International Reports. 7:2321
Autor:
G. Remuzzi, B. Dixon, F. Fakhouri, M. Pickering, T. Cook, D. Kavanagh, P. Walker, C. Licht, G. Appel, M. Vivarelli, Z. Zhang, L. Li, H. Kocinsky
Publikováno v:
Kidney International Reports. 7:S459
Autor:
D. Apelian, Edward Gane, H. Kocinsky, M. Donohue, H. Robison, M. Mader, Christian Schwabe, V. Suri, M. Huang, James Hui, J. Yang
Publikováno v:
Journal of Hepatology. 62:S266
Autor:
J. Fabrycki, Y. Zhao, D. Patel, Milind Deshpande, S. Podos, W. Yang, L. Robarge, H. Kocinsky, M. Huang, G. Yang, H. Robison
Publikováno v:
Journal of Hepatology. 58:S487-S488
Autor:
A. Muir, Thomas Marbury, A. Agarwal, Milind Deshpande, L. Robarge, M. Huang, J. Hill, E.J. Lawitz, James Hui, H. Robison, A. Perelson, H. Kocinsky
Publikováno v:
Journal of Hepatology. 58:S360
The primary objective(s) of this study were: Results: ACH-3102 was safe and well tolerated in patients with GT-1 chronic HCV infection at doses of 25 mg, 50 mg, 150 mg and 300 mg. There were no serious adverse events, and no discontinuations for safe
Autor:
D. Patel, G. Yang, H. Robison, Milind Deshpande, M. Huang, S. Podos, L. Robarge, H. Kocinsky, J. Fabrycki, Y. Zhao, W. Yang, E. Olek
Publikováno v:
Journal of Hepatology. 58:S488
Autor:
D. Patel, L. Robarge, Y. Zhao, M. Huang, A. Agarwal, B. Zhang, Milind Deshpande, E. Olek, J. Fabrycki, H. Kocinsky, James Hui, G. Yang, H. Robison
Publikováno v:
Journal of Hepatology. 58:S319
Autor:
A. Murillo, H. Robison, Thomas Marbury, M. Huang, Bradley D. Vince, M. Demicco, J. Hill, E.J. Lawitz, James Hui, A. Agarwal, L. Robarge, Milind Deshpande, H. Kocinsky, D. Gruener, E. Olek
Publikováno v:
Journal of Hepatology. 58:S347
Background: ACH-2684 is a second-generation HCV NS3 protease inhibitor in Phase Ib development for the treatment of chronic HCV infection. ACH-2684 demonstrates potent activity in vitro against genotype-1 (GT1) HCV and, as compared to other protease
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.